Thrivent Financial For Lutherans increased its position in shares of Laboratory Corporation of America Holdings (NYSE:LH) by 11.7% during the second quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 4,200 shares of the medical research company’s stock after acquiring an additional 440 shares during the period. Thrivent Financial For Lutherans’ holdings in Laboratory Corporation of America Holdings were worth $647,000 at the end of the most recent reporting period.

A number of other hedge funds have also recently modified their holdings of the stock. Sandy Spring Bank grew its position in Laboratory Corporation of America Holdings by 1.8% during the 2nd quarter. Sandy Spring Bank now owns 27,958 shares of the medical research company’s stock worth $4,309,000 after acquiring an additional 490 shares during the last quarter. PNC Financial Services Group Inc. grew its position in Laboratory Corporation of America Holdings by 2.3% during the 2nd quarter. PNC Financial Services Group Inc. now owns 39,891 shares of the medical research company’s stock worth $6,150,000 after acquiring an additional 881 shares during the last quarter. Profund Advisors LLC grew its position in Laboratory Corporation of America Holdings by 6.6% during the 2nd quarter. Profund Advisors LLC now owns 4,370 shares of the medical research company’s stock worth $674,000 after acquiring an additional 271 shares during the last quarter. Laurion Capital Management LP bought a new stake in Laboratory Corporation of America Holdings during the 2nd quarter worth $709,000. Finally, Amalgamated Bank grew its position in Laboratory Corporation of America Holdings by 52.3% during the 2nd quarter. Amalgamated Bank now owns 11,341 shares of the medical research company’s stock worth $1,748,000 after acquiring an additional 3,896 shares during the last quarter. Institutional investors and hedge funds own 93.19% of the company’s stock.

In other news, CEO David P. King sold 132,713 shares of the firm’s stock in a transaction dated Tuesday, September 5th. The stock was sold at an average price of $157.06, for a total transaction of $20,843,903.78. The sale was disclosed in a legal filing with the SEC, which is available through the SEC website. Also, Director R Sanders Williams sold 3,100 shares of the firm’s stock in a transaction dated Friday, August 11th. The stock was sold at an average price of $156.88, for a total value of $486,328.00. Following the completion of the sale, the director now directly owns 10,073 shares in the company, valued at $1,580,252.24. The disclosure for this sale can be found here. Insiders have sold 222,968 shares of company stock worth $34,980,922 over the last ninety days. Insiders own 0.90% of the company’s stock.

COPYRIGHT VIOLATION WARNING: This report was first reported by Daily Political and is the sole property of of Daily Political. If you are reading this report on another publication, it was illegally copied and reposted in violation of United States and international copyright laws. The original version of this report can be viewed at https://www.dailypolitical.com/2017/10/13/thrivent-financial-for-lutherans-raises-position-in-laboratory-corporation-of-america-holdings-lh.html.

LH has been the topic of a number of research reports. Craig Hallum restated a “buy” rating and set a $179.00 price objective (up previously from $157.00) on shares of Laboratory Corporation of America Holdings in a research report on Thursday, July 27th. Wells Fargo & Company initiated coverage on Laboratory Corporation of America Holdings in a research report on Thursday. They set an “outperform” rating and a $175.00 price objective on the stock. Morgan Stanley boosted their price objective on Laboratory Corporation of America Holdings from $154.00 to $166.00 and gave the stock an “overweight” rating in a research report on Thursday, August 10th. Zacks Investment Research upgraded Laboratory Corporation of America Holdings from a “hold” rating to a “buy” rating and set a $170.00 price objective on the stock in a research report on Tuesday. Finally, BidaskClub upgraded Laboratory Corporation of America Holdings from a “buy” rating to a “strong-buy” rating in a research report on Wednesday, June 28th. Six analysts have rated the stock with a hold rating, nine have issued a buy rating and one has given a strong buy rating to the stock. Laboratory Corporation of America Holdings presently has a consensus rating of “Buy” and a consensus price target of $168.15.

Laboratory Corporation of America Holdings (NYSE:LH) last announced its quarterly earnings data on Wednesday, July 26th. The medical research company reported $2.47 earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of $2.40 by $0.07. Laboratory Corporation of America Holdings had a return on equity of 16.85% and a net margin of 7.57%. The firm had revenue of $2.50 billion for the quarter, compared to analysts’ expectations of $2.47 billion. During the same period last year, the firm earned $2.36 earnings per share. The company’s revenue for the quarter was up 4.9% compared to the same quarter last year.

Laboratory Corporation of America Holdings Profile

Laboratory Corporation of America Holdings is a life sciences company that is integrated in guiding patient care, providing clinical laboratory and end-to-end drug development services. The Company operates as a healthcare diagnostics company. The Company operates through two segments: LabCorp Diagnostics (LCD) and Covance Drug Development (CDD).

Institutional Ownership by Quarter for Laboratory Corporation of America Holdings (NYSE:LH)

Receive News & Ratings for Laboratory Corporation of America Holdings Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Laboratory Corporation of America Holdings and related companies with MarketBeat.com's FREE daily email newsletter.